IMMUNOME INC (IMNM) Stock News
NASDAQ:IMNM - Nasdaq - US45257U1088 - Common Stock - Currency: USD
IMNM Latest News, Press Releases and Analysis
Immunome Announces Pricing of Upsized Public Offering of Common Stock
Curious about the stocks that are showing activity after the closing bell on Wednesday?
After the closing bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Immunome Announces Proposed Public Offering of Common Stock
Hummingbird Bioscience Licenses Novel Antibodies to Immunome
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 Small-Cap Stocks With Big Growth Potential
Small-cap companies may give investors more targeted exposure to the U.S. economy; these companies are three leaders in the space.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference
Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update
Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation Conference
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021
Immunome Appoints Roee Shahar as Executive Vice President, Commercial
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
Immunome Stock Sees RS Rating Jump To 91
Immunome stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 88 to 91.
IMNM Stock Earnings: Immunome Misses EPS, Misses Revenue for Q2 2024
IMNM stock results show that Immunome missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
IMNM Stock Earnings: Immunome Misses EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Immunome (NASDAQ:IMNM) just reported results for the second quarter of 2024.Imm...
Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update
Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities
Nectin Therapeutics Licenses Novel Antibodies to Immunome
/PRNewswire/ -- Nectin Therapeutics, Ltd., a biotechnology company developing novel immunotherapies and antibody drug conjugates (ADC) to address tumor...
